A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease

Background: We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high...

Full description

Saved in:
Bibliographic Details
Published inDiabetes & metabolism journal Vol. 48; no. 4; pp. 740 - 751
Main Authors Choi, Seung Joon, Yoon, Sungjin, Kim, Kyoung-Kon, Kim, Doojin, Lee, Hye Eun, Kim, Kwang Gi, Shin, Seung Kak, Park, Ie Byung, Kim, Seong Min, Lee, Dae Ho
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Diabetes Association / Daehan Dangnyobyeong Hakoe 01.07.2024
Korean Diabetes Association
대한당뇨병학회
Subjects
Adult
Aged
akr1b10 protein, human
Alanine Transaminase - blood
Alcohol
Aldehyde Reductase - blood
Aldo-Keto Reductases - blood
Aspartate Aminotransferases - blood
Biomarkers
Biomarkers - blood
Biopsy
Case-Control Studies
Clinical trials
Cytokeratin
Disease Progression
Fatty liver
Female
Gastrointestinal surgery
Humans
keratin-18
Keratin-18 - blood
Liver - diagnostic imaging
Liver - pathology
Liver cancer
Liver cirrhosis
Liver Cirrhosis - blood
Liver Cirrhosis - diagnosis
Liver Cirrhosis - diagnostic imaging
Liver diseases
Liver transplants
Magnetic resonance imaging
Male
Middle Aged
non-alcoholic fatty liver disease
Non-alcoholic Fatty Liver Disease - blood
Original
Proteins
ROC Curve
Variance analysis
Weight control
내과학
Biomarkers
Magnetic resonance imaging
Non-alcoholic fatty liver disease
Keratin-18
AKR1B10 protein, human
Online AccessGet full text

Cover

Abstract Background: We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis).Methods: A total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination.Results: A composite blood biomarker comprised of AKR1B10, CK-18, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) showed excellent performance for the diagnosis of, NASH, advanced fibrosis, and high-risk NASH, with area under the receiver operating characteristic curve values of 0.934 (95% confidence interval [CI], 0.888 to 0.981), 0.902 (95% CI, 0.832 to 0.971), and 0.918 (95% CI, 0.862 to 0.974), respectively. However, the performance of this blood composite biomarker was inferior to that various magnetic resonance (MR)-based composite biomarkers, such as proton density fat fraction/MR elastography- liver stiffness measurement (MRE-LSM)/ALT/AST for NASH, MRE-LSM+fibrosis-4 index for advanced fibrosis, and the known MR imaging-AST (MAST) score for high-risk NASH.Conclusion: Our blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available.
AbstractList Background: We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis).Methods: A total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination.Results: A composite blood biomarker comprised of AKR1B10, CK-18, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) showed excellent performance for the diagnosis of, NASH, advanced fibrosis, and high-risk NASH, with area under the receiver operating characteristic curve values of 0.934 (95% confidence interval [CI], 0.888 to 0.981), 0.902 (95% CI, 0.832 to 0.971), and 0.918 (95% CI, 0.862 to 0.974), respectively. However, the performance of this blood composite biomarker was inferior to that various magnetic resonance (MR)-based composite biomarkers, such as proton density fat fraction/MR elastography- liver stiffness measurement (MRE-LSM)/ALT/AST for NASH, MRE-LSM+fibrosis-4 index for advanced fibrosis, and the known MR imaging-AST (MAST) score for high-risk NASH.Conclusion: Our blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available. KCI Citation Count: 0
Background We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis).* Methods A total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination.* Results A composite blood biomarker comprised of AKR1B10, CK-18, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) showed excellent performance for the diagnosis of, NASH, advanced fibrosis, and high-risk NASH, with area under the receiver operating characteristic curve values of 0.934 (95% confidence interval [CI], 0.888 to 0.981), 0.902 (95% CI, 0.832 to 0.971), and 0.918 (95% CI, 0.862 to 0.974), respectively. However, the performance of this blood composite biomarker was inferior to that various magnetic resonance (MR)-based composite biomarkers, such as proton density fat fraction/MR elastography-liver stiffness measurement (MRE-LSM)/ALT/AST for NASH, MRE-LSM+fibrosis-4 index for advanced fibrosis, and the known MR imaging-AST (MAST) score for high-risk NASH.* Conclusion Our blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available.
We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis).BACKGRUOUNDWe aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis).A total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination.METHODSA total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination.A composite blood biomarker comprised of AKR1B10, CK-18, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) showed excellent performance for the diagnosis of, NASH, advanced fibrosis, and high-risk NASH, with area under the receiver operating characteristic curve values of 0.934 (95% confidence interval [CI], 0.888 to 0.981), 0.902 (95% CI, 0.832 to 0.971), and 0.918 (95% CI, 0.862 to 0.974), respectively. However, the performance of this blood composite biomarker was inferior to that various magnetic resonance (MR)-based composite biomarkers, such as proton density fat fraction/MR elastography- liver stiffness measurement (MRE-LSM)/ALT/AST for NASH, MRE-LSM+fibrosis-4 index for advanced fibrosis, and the known MR imaging-AST (MAST) score for high-risk NASH.RESULTSA composite blood biomarker comprised of AKR1B10, CK-18, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) showed excellent performance for the diagnosis of, NASH, advanced fibrosis, and high-risk NASH, with area under the receiver operating characteristic curve values of 0.934 (95% confidence interval [CI], 0.888 to 0.981), 0.902 (95% CI, 0.832 to 0.971), and 0.918 (95% CI, 0.862 to 0.974), respectively. However, the performance of this blood composite biomarker was inferior to that various magnetic resonance (MR)-based composite biomarkers, such as proton density fat fraction/MR elastography- liver stiffness measurement (MRE-LSM)/ALT/AST for NASH, MRE-LSM+fibrosis-4 index for advanced fibrosis, and the known MR imaging-AST (MAST) score for high-risk NASH.Our blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available.CONCLUSIONOur blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available.
We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis). A total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination. A composite blood biomarker comprised of AKR1B10, CK-18, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) showed excellent performance for the diagnosis of, NASH, advanced fibrosis, and high-risk NASH, with area under the receiver operating characteristic curve values of 0.934 (95% confidence interval [CI], 0.888 to 0.981), 0.902 (95% CI, 0.832 to 0.971), and 0.918 (95% CI, 0.862 to 0.974), respectively. However, the performance of this blood composite biomarker was inferior to that various magnetic resonance (MR)-based composite biomarkers, such as proton density fat fraction/MR elastography- liver stiffness measurement (MRE-LSM)/ALT/AST for NASH, MRE-LSM+fibrosis-4 index for advanced fibrosis, and the known MR imaging-AST (MAST) score for high-risk NASH. Our blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available.
Author Lee, Hye Eun
Yoon, Sungjin
Park, Ie Byung
Kim, Seong Min
Lee, Dae Ho
Kim, Doojin
Kim, Kwang Gi
Kim, Kyoung-Kon
Choi, Seung Joon
Shin, Seung Kak
Author_xml – sequence: 1
  givenname: Seung Joon
  orcidid: 0000-0003-3861-7682
  surname: Choi
  fullname: Choi, Seung Joon
– sequence: 2
  givenname: Sungjin
  orcidid: 0000-0002-7030-841X
  surname: Yoon
  fullname: Yoon, Sungjin
– sequence: 3
  givenname: Kyoung-Kon
  surname: Kim
  fullname: Kim, Kyoung-Kon
– sequence: 4
  givenname: Doojin
  surname: Kim
  fullname: Kim, Doojin
– sequence: 5
  givenname: Hye Eun
  surname: Lee
  fullname: Lee, Hye Eun
– sequence: 6
  givenname: Kwang Gi
  surname: Kim
  fullname: Kim, Kwang Gi
– sequence: 7
  givenname: Seung Kak
  surname: Shin
  fullname: Shin, Seung Kak
– sequence: 8
  givenname: Ie Byung
  surname: Park
  fullname: Park, Ie Byung
– sequence: 9
  givenname: Seong Min
  orcidid: 0000-0002-6453-5253
  surname: Kim
  fullname: Kim, Seong Min
– sequence: 10
  givenname: Dae Ho
  orcidid: 0000-0002-8832-3052
  surname: Lee
  fullname: Lee, Dae Ho
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38311058$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003103628$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1kk1vEzEQhleoiJbSI1dkiQtCSvDY-2GfUBIoRESAqnC2HK83dbLxpPamUvj1eJMS0Ur4MpbnmVcz4_dldubR2yx7DXSYU8k_1JvVkFHGhxSEfJZdMMb5oKSiOjvdK3meXcW4ounkglaVfJGdc8EBaCEust8jMsHNFqPrLBm3iDUZO9zosLaBTL1pd7XzSzL6dgNjoET7mkz2Haas7pwnIEiDgfwMuAw2RndvyXy_tZFgQ76j163BW2ydIde66_ZkloBAPrlodbSvsueNbqO9eoiX2a_rz_PJ18Hsx5fpZDQbmAKqbmCFYRJYLhgHakSajtFFRRe8NlWaQ1ouQNtcChC8BkZrXlOQFoA1ogGx4JfZ-6OuD41aG6dQu0NcoloHNbqZT1VaRiGhZAmeHuEa9Uptg0ur2B8qDg8YlkqHzpnWqpKbXIOmui5YLquFbBomS1My0wjBJE9aH49a291iY2tjfRd0-0j0cca729TUvQLgtAKQSeHdg0LAu52Nndq4aGzbam9xFxWTjOUFzcseffsEXeEupB-IijMQUDBeQqLe_NvSqZe_hkjA4AiYgDEG25wQoKr3nEqeU73nVO-5xPMnvHFdsgb2E7n2P1V_APsq1q8
CitedBy_id crossref_primary_10_1016_j_cca_2025_120147
crossref_primary_10_3390_plants14030349
crossref_primary_10_1016_j_cbi_2024_111111
Cites_doi 10.1016/j.jhep.2019.04.019
10.3390/ijms23095035
10.3390/metabo11060332
10.1056/nejm200102153440706
10.1002/hep.29367
10.1016/j.jhep.2022.07.020
10.1016/j.jhep.2021.11.012
10.4093/dmj.2020.0010
10.1007/s00535-019-01551-3
10.1126/scitranslmed.aba4448
10.3390/cancers11040486
10.1002/hep4.1971
10.1038/s41395-018-0088-6
10.1074/jbc.m113.514877
10.1002/hep.28431
10.1053/j.gastro.2020.01.052
10.4093/dmj.2020.0137
10.1016/j.jhep.2016.06.005
10.1038/s41598-020-71995-8
10.3803/enm.2020.35.2.243
10.1002/hep.23050
10.1002/hep.21669
10.1016/j.jhepr.2019.06.004
10.1016/j.jhep.2013.09.002
10.1056/nejmoa2029349
10.1124/dmd.105.007971
10.1016/j.jhep.2020.02.027
10.1016/j.jhep.2020.06.025
10.1002/hep.21223
10.1016/s2468-1253(19)30383-8
10.1136/gutjnl-2020-322976
10.1016/j.jhep.2022.07.004
10.1016/j.cgh.2021.09.041
10.1002/hep.29477
10.1002/hep.20701
10.1016/j.jhep.2012.05.019
ContentType Journal Article
Copyright 2024. This work is licensed under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2024 Korean Diabetes Association 2024
Copyright_xml – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2024 Korean Diabetes Association 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
ACYCR
DOI 10.4093/dmj.2023.0189
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database

MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2233-6087
EndPage 751
ExternalDocumentID oai_kci_go_kr_ARTI_10559162
oai_doaj_org_article_63c4a1a0ad52497b9ff296c62cf88293
PMC11307119
38311058
10_4093_dmj_2023_0189
Genre Journal Article
GrantInformation_xml – fundername: National Research Foundation of Korea
  grantid: 2019R1I1A2A02062305
– fundername: Ministry of Health and Welfare
  grantid: HI14C1135
– fundername: Gachon University Gil Medical Center
  grantid: FRD2021-03
– fundername: National Research Foundation of Korea
  grantid: 2021R1A5A2030333
– fundername: Ministry of Science and ICT
– fundername: Korea Health Industry Development Institute
– fundername: Ministry of Education
GroupedDBID 5-W
5VS
7RV
7X7
88E
8FI
8FJ
8JR
8XY
9ZL
AAYXX
ABDBF
ABUWG
ADBBV
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
CITATION
DIK
EF.
FYUFA
GROUPED_DOAJ
HMCUK
HYE
KQ8
M1P
M48
NAPCQ
O5R
O5S
PGMZT
PHGZM
PHGZT
PIMPY
PSQYO
RPM
UKHRP
ADRAZ
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
PJZUB
PPXIY
RIG
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ACYCR
OK1
ID FETCH-LOGICAL-c517t-e8c2912482310c860820b70b3dc73839e381ae498183d120d3d019e112f8f18b3
IEDL.DBID M48
ISSN 2233-6079
2233-6087
IngestDate Thu Jan 09 03:21:57 EST 2025
Wed Aug 27 01:31:23 EDT 2025
Thu Aug 21 18:31:52 EDT 2025
Thu Jul 10 18:48:02 EDT 2025
Fri Jul 25 09:28:55 EDT 2025
Mon Jul 21 06:01:13 EDT 2025
Thu Apr 24 22:59:22 EDT 2025
Tue Jul 01 03:40:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Biomarkers
Magnetic resonance imaging
Non-alcoholic fatty liver disease
Keratin-18
AKR1B10 protein, human
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c517t-e8c2912482310c860820b70b3dc73839e381ae498183d120d3d019e112f8f18b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Seung Joon Choi and Sungjin Yoon contributed equally to this study as first authors.
https://e-dmj.org/journal/view.php?number=2821
ORCID 0000-0003-3861-7682
0000-0002-8832-3052
0000-0002-7030-841X
0000-0002-6453-5253
OpenAccessLink https://doaj.org/article/63c4a1a0ad52497b9ff296c62cf88293
PMID 38311058
PQID 3218152361
PQPubID 7191758
PageCount 12
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10559162
doaj_primary_oai_doaj_org_article_63c4a1a0ad52497b9ff296c62cf88293
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11307119
proquest_miscellaneous_2922450469
proquest_journals_3218152361
pubmed_primary_38311058
crossref_primary_10_4093_dmj_2023_0189
crossref_citationtrail_10_4093_dmj_2023_0189
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-07-01
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
– name: Sŏul
PublicationTitle Diabetes & metabolism journal
PublicationTitleAlternate Diabetes Metab J
PublicationYear 2024
Publisher Korean Diabetes Association / Daehan Dangnyobyeong Hakoe
Korean Diabetes Association
대한당뇨병학회
Publisher_xml – name: Korean Diabetes Association / Daehan Dangnyobyeong Hakoe
– name: Korean Diabetes Association
– name: 대한당뇨병학회
References ref13
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
Cusi (ref35) 2022
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref6
  doi: 10.1016/j.jhep.2019.04.019
– ident: ref15
  doi: 10.3390/ijms23095035
– ident: ref18
  doi: 10.3390/metabo11060332
– ident: ref32
  doi: 10.1056/nejm200102153440706
– ident: ref2
  doi: 10.1002/hep.29367
– ident: ref8
  doi: 10.1016/j.jhep.2022.07.020
– ident: ref29
  doi: 10.1016/j.jhep.2021.11.012
– ident: ref34
  doi: 10.4093/dmj.2020.0010
– ident: ref19
  doi: 10.1007/s00535-019-01551-3
– ident: ref16
  doi: 10.1126/scitranslmed.aba4448
– ident: ref20
  doi: 10.3390/cancers11040486
– ident: ref13
  doi: 10.1002/hep4.1971
– ident: ref4
  doi: 10.1038/s41395-018-0088-6
– ident: ref21
  doi: 10.1074/jbc.m113.514877
– ident: ref1
  doi: 10.1002/hep.28431
– ident: ref3
  doi: 10.1053/j.gastro.2020.01.052
– ident: ref26
  doi: 10.4093/dmj.2020.0137
– ident: ref23
  doi: 10.1016/j.jhep.2016.06.005
– ident: ref25
  doi: 10.1038/s41598-020-71995-8
– ident: ref10
  doi: 10.3803/enm.2020.35.2.243
– ident: ref14
  doi: 10.1002/hep.23050
– ident: ref30
  doi: 10.1002/hep.21669
– ident: ref11
  doi: 10.1016/j.jhepr.2019.06.004
– start-page: 528
  volume-title: American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)
  year: 2022
  ident: ref35
– ident: ref37
  doi: 10.1016/j.jhep.2013.09.002
– ident: ref5
  doi: 10.1056/nejmoa2029349
– ident: ref17
  doi: 10.1124/dmd.105.007971
– ident: ref36
  doi: 10.1016/j.jhep.2020.02.027
– ident: ref33
  doi: 10.1016/j.jhep.2020.06.025
– ident: ref12
  doi: 10.1002/hep.21223
– ident: ref27
  doi: 10.1016/s2468-1253(19)30383-8
– ident: ref28
  doi: 10.1136/gutjnl-2020-322976
– ident: ref7
  doi: 10.1016/j.jhep.2022.07.004
– ident: ref24
  doi: 10.1016/j.cgh.2021.09.041
– ident: ref9
  doi: 10.1002/hep.29477
– ident: ref31
  doi: 10.1002/hep.20701
– ident: ref22
  doi: 10.1016/j.jhep.2012.05.019
SSID ssj0000480779
Score 2.3468456
Snippet Background: We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a...
We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic...
Background We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a...
SourceID nrf
doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 740
SubjectTerms Adult
Aged
akr1b10 protein, human
Alanine Transaminase - blood
Alcohol
Aldehyde Reductase - blood
Aldo-Keto Reductases - blood
Aspartate Aminotransferases - blood
Biomarkers
Biomarkers - blood
Biopsy
Case-Control Studies
Clinical trials
Cytokeratin
Disease Progression
Fatty liver
Female
Gastrointestinal surgery
Humans
keratin-18
Keratin-18 - blood
Liver - diagnostic imaging
Liver - pathology
Liver cancer
Liver cirrhosis
Liver Cirrhosis - blood
Liver Cirrhosis - diagnosis
Liver Cirrhosis - diagnostic imaging
Liver diseases
Liver transplants
Magnetic resonance imaging
Male
Middle Aged
non-alcoholic fatty liver disease
Non-alcoholic Fatty Liver Disease - blood
Original
Proteins
ROC Curve
Variance analysis
Weight control
내과학
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hHhAXxBtDQYtAnHC7D3u9PiaFqDxaIUSl3lbrfYBJa1eJU6n8emZsN0oQiAunSPZacmZmd77JfPmGkFfcwSFXQZGjpPBpJoJMrQ4xZcIpz22mK4cd3aNjdXiSfTjNTzdGfSEnbJAHHgy3r6TLLLfM-hwqhaIqYxSlckq4COCw7HU-IedtFFP9GYz_lO6F9iD9yVSxohwENqGckfv-_Mcejg3fYxzHu28kpF63H9JMs4h_gpy_Myc3UtHsDrk9Ykg6Gd79LrkRmnvk5tHYJb9Pfk4obnOkYwU6RWY6ndbtORJxFhQOhLMVJiw6-fiFTzmjtvH04Kpr56ivXDeUawpIln5G5haSZC8DxWp1SdtIjxG490N1a0dntuuu6CdkdtC3Q6PnATmZvft6cJiOMxZSl_OiS4N2ooQcj91A5rRCRFAVrJLeFVC8lgEyug1ZCXldei6Ylx5AYQCUFnXkupIPyU7TNuExocpGx7TLoi9s5qTTlWY2d04ogEDR24S8uTa0caMAOc7BODNQiKBfDPjFoF8M-iUhr9fLLwbljb8tnKLX1otQMLu_AGFkxjAy_wqjhLwEn5u5q_vn8fNba-YLA2XFe4NTRAFHi4TsXseEGff60khESTmK2CTkxfo27FJsvdgmtKulESVApRx_i0jIoyGE1u8LZgYMluuE6K3g2vpC23ea-nuvBM4BgRScl0_-hwmekltg02zgIu-SnW6xCs8AcXXV835z_QKzfyTx
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k1KQUYgTqS14zycE9otrMqjFUJU2pvl-FHCtkmbzSKVX89Mkg1dBJwibbxS4hl7vvF8-YaQl9zAJldAkpOKyIZx5ESopfMhi0xquY5lYbCie3iUHhzHH-bJfDhwWw60yvWe2G3UtjZ4Rr4nMBYlKBXy5vwixK5RWF0dWmhcJzdQugwpXdk8G89Yuu-lO7k9CIIiTFmW9zKbkNSIPXv2fRebh-8yjk3er4SlTr0fgk3V-L8Bzz_5k1cC0uwOuT0gSTrpTX-XXHPVPXLzcKiV3yc_JxQXO5KyHJ0iP51Oy_oM6TgNhW3hdIVhi04-fuFTzqiuLN2_bOsFqiyXFeWSAp6ln5G_hVTZH45izrqktadHCN-71rqloTPdtpf0E_I76Nu-3POAHM_efd0_CIdOC6FJeNaGTpooh0iPNUFmZIq4oMhYIazJIIXNHcR17eIcoruwPGJWWICGDrCal57LQjwkW1VduceEptobJk3sbaZjI4wsJNOJMVEKQMhbHZDX64lWZpAhx24YpwrSEbSLArsotItCuwTk1Tj8vNff-NfAKVptHISy2d0PdXOihlWoUmFizTXTNoG0Myty76M8NWlkPGQauQjIC7C5Wpiy-z9eT2q1aBQkF-8V9hIFNB0FZGftE2pY8Uv12z8D8ny8DWsVCzC6cvVqqaIcAFOCJxIBedS70Pi8MM2AxBIZELnhXBsvtHmnKr91euAccEgG_r_9_-d6Qm7BbMU913iHbLXNyj0FRNUWz7pl8wtUxxyS
  priority: 102
  providerName: ProQuest
Title A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
URI https://www.ncbi.nlm.nih.gov/pubmed/38311058
https://www.proquest.com/docview/3218152361
https://www.proquest.com/docview/2922450469
https://pubmed.ncbi.nlm.nih.gov/PMC11307119
https://doaj.org/article/63c4a1a0ad52497b9ff296c62cf88293
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003103628
Volume 48
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Diabetes and Metabolism Journal, 2024, 48(4), 204, pp.740-751
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3db9MwELfYJk17QXwvMCojEE-kxHE-nCfUjlWD0WpMVOqb5djOKO0SSFNE-eu5S9KywvaSSIkTJb473--Xu9wR8oppWORSIDkR940b-Ja7StjM9XwdGaYCkWqM6A5H0ek4-DgJJ39LCrUTuLiR2mE_qXE57_76sXoHBg_4tQvshL81V9-62AW86zGR7JA9cEox2uiwRfr1ooy_TsdJU2Xz_6sOyD5QNXCF2Pr9moOq6_iD28nL7CYI-m8m5TXXNLhH7raYkvYaJbhP7tj8AdkftlHzh-R3j6LZY3qWpX3MVKf9aXGFiTklhQVivkQHRntnF6zPPKpyQ49XVTHDesvTnDJBAdnSc8zkwqTZn5Yie13QIqMjBPJ1k92ppgNVVSv6CTM96Psm8POIjAcnX45P3bbngqtDFleuFdpPwOdjdNDTIkKEkMZeyo2OYYYSCx5e2SABP88N8z3DDYBEC6gtExkTKX9MdvMit4eERirTntBBZmIVaK5FKjwVau1HAIkyoxzyZj3RUrcFybEvxlwCMUERSRCRRBFJFJFDXm-Gf28qcdw2sI9S2wzCAtr1gaK8lK09yojrQDHlKRMCAY3TJMv8JNKRrzPgHAl3yEuQuZzpaX097i8LOSsl0IwPEruKAq72HXK01gm5Vl3JETWFWNTGIS82p8FqMRSjclssF9JPADqF-G3CIU8aFdo871oRHSK2lGvrhbbP5NOvdWVwBogkZix5eutNn5EDmKigSTg-IrtVubTPAVZVaYfsxJO4Q_b6J6Pzi079cQK2Z59FpzalP3sQIY0
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEviDuBAUZcnsgW27k4Dwi126qWXjRNm7Q3z3GcUboloxdQ-VH8Rs5J0rIi4G1PlRq3Snzs832fz8k5hLxhBpxcAiInFDx1fW6Fq6XNXI-bMGXal4nBiO5gGHaO_U8nwckG-bl8FwbTKpc-sXTUaWHwjHxHIBYFWCrk4-VXF7tGYXR12UKjWhY9u_gOkm36obsH9n3LeXv_aLfj1l0FXBOwaOZaaXgMqIbxL8_IEDEwibxEpCYCuRZbwDBt_RiQTKSMe6lIgQZZ4CWZzJhMBPzvDbLpC5AyDbLZ2h8eHK5Odco3tMsCfwC7wg29KK4Ke4KMEjvpxZdtbFe-7TFsK38FCMt-AQBv-ST7G9X9M2PzCgS275I7NXelzWqx3SMbNr9Pbg7q6PwD8qNJ0b1gGpilLcyIp61RcYEJQBMKjuh8jkBJm71D1mIe1XlKdxezYox1nUc5ZZICg6YHmDGGybnfLEWVPKVFRocoGMpmviND23o2W9A-ZpTQvSrA9JAcX4sVHpFGXuT2CaGhzownjZ-lkfaNMDKRng6M4SFQryzVDnm_nGhl6sLn2H_jXIEAQrsosItCuyi0i0PerYZfVhU__jWwhVZbDcJC3eUXxeRM1ftehcL4mmlPpwEI3SiJs4zHoQm5yUDbxMIhr8HmamxG5e_x86xQ44kCOdNV2L0U-Dt3yNZyTajax0zV7x3hkFery-AdMOSjc1vMp4rHQNECPANxyONqCa3uF6YZuF8gHSLXFtfaA61fyUefywrkDJhPxFj89P_39ZLc6hwN-qrfHfaekdswc36V6bxFGrPJ3D4HPjdLXtSbiJLT6963vwBLzFfj
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Composite+Blood+Biomarker+Including+AKR1B10+and+Cytokeratin+18+for+Progressive+Types+of+Nonalcoholic+Fatty+Liver+Disease&rft.jtitle=Diabetes+%26+metabolism+journal&rft.au=Choi%2C+Seung+Joon&rft.au=Yoon%2C+Sungjin&rft.au=Kim%2C+Kyoung-Kon&rft.au=Kim%2C+Doojin&rft.date=2024-07-01&rft.eissn=2233-6087&rft.volume=48&rft.issue=4&rft.spage=740&rft_id=info:doi/10.4093%2Fdmj.2023.0189&rft_id=info%3Apmid%2F38311058&rft.externalDocID=38311058
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2233-6079&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2233-6079&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2233-6079&client=summon